>>One clinical approach to treating angiogenic vision loss, he says, could be to deliver the TrpRS molecules directly into the eye through gene- and cell-based vectors.<<
Could these molecules be eluted from a device?
p.s. Another good find, Katie.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”